The Ideal Pharma Country Manager: China (Egon Zehnder)
Lydia Guo, Grace Zhao and Mendy Zhang of executive search firm Egon Zehnder outline some of the latest trends affecting the Chinese pharma sector and what they look for in…
Yangtze River Pharmaceutical Group is a Chinese multinational pharmaceutical corporation headquartered in Taizhou, Jiangsu Province in the People’s Republic of China, and with its research headquarters in Shanghai. It is one of the Asia’s largest pharmaceutical companies by revenues, and was listed in 2014 as being China’s second largest pharmaceutical manufacturer, and leading company for technological and entrepreneurial innovation.
Founded in 1971, the Yangtze River Pharmaceutical Group started as a local firm providing drugstores and hospitals with vitamin supplements and pain medication. For much of its early existence, profit margins were low due to the YRPG’s inability to expand a fledgeling sales network past a local level. This changed at the end of the 20th century when sweeping economic and medical reforms placed an ever-increasing demand on quality drug production.[5] Located in a prime location between the major cities of Shanghai, Suzhou, and Hangzhou, the YRPG quickly expanded its business profile. The group has experienced significant growth in the past decade, having quadrupled their net income between 2003-2010.[1] In the fiscal year 2014, board shareholders received a record 560% return on investment, and company assets rapidly expanded.[1] The company also hosts 22 subsidiary firms across Asia and has exploratory ventures in Europe, Canada, and the United States.
Lydia Guo, Grace Zhao and Mendy Zhang of executive search firm Egon Zehnder outline some of the latest trends affecting the Chinese pharma sector and what they look for in…
Jay Dong, founding GM (China and APAC) and Global VP of Cell Signaling Technology, shares the company’s success in the past ten years; the economic transformation in China driving the…
Kevin Rufang Huang is the president and founder of the Chinese Organization for Rare Disorders (CORD). A rare disease patient himself, he is responsible for bringing“International Rare Disease Day” to…
What do executive recruitment firms look for when hiring country managers for multinational pharma companies in some of the world’s most challenging markets? Eric Bouteiller and Simon Wan of Cornerstone…
Dr Lingshi Tan, chairman and CEO of dMed, shares his strategic insights into the new era of Chinese biotech innovation and how it motivated him to leave Pfizer to establish…
Dr John Gong, CEO of 3D Medicines, shares the company’s ‘3D – diagnostics, data, and drug development’ approach to cancer precision medicine; his philosophy of putting patient needs at the…
China is planning to establish a new national medical ethics committee in the wake of the “CRISPR babies” scandal. The committee will not be limited to overseeing gene editing…
Yuichi Yomasu, president of Daiichi Sankyo China, shares his first impressions of the dynamic but complex Chinese market since he assumed position ten months ago; the strategic importance of the…
Harbour BioMed is a fast-growing global biotech company with facilities in Rotterdam, Boston and Shanghai. The company is laser-focused on developing both proprietary and in-licensed immunological therapies using their state-of-the-art…
Tian Wee Ng, managing director (Asia-Pacific) for Pierre Fabre Medicament, shares insight on how the business has evolved in the region, moving from an opportunistic approach to a more strategic…
Rogers Luo Yongqing, global VP and general manager (China), Gilead Sciences, shares the key accomplishments of Gilead in China with six innovative products approved in just 15 months; the strategic…
While others have failed during the last 30 years, Hua Medicine has finally succeeded in developing a breakthrough diabetes treatment controlling blood glucose levels by taking a novel approach and…
See our Cookie Privacy Policy Here